On September 8, 2022, Photys Therapeutics, Inc. closed the transaction. The round of funding led by MPM Asset Management, L.L.C.. The transaction included participation from Omega Fund Management, LLC, Longwood Fund, 8VC, Arkin Bio Venture Partners Ltd., Mass General Brigham Ventures, LLC, MRL Ventures Fund, Merck Global Health Innovation Fund, LLC, Eli Lilly and Company , Heritage Medical Systems, Inc.